Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCRX.L Regulatory News (CRX)

  • There is currently no data for CRX

Directorate Change

25 Feb 2009 07:00

RNS Number : 8182N
Cyprotex PLC
25 February 2009
 



25 February 2009

Cyprotex PLC ('Cyprotex' or the 'Company')

Directorate changes

Cyprotex PLC (AIM: CRX) today announces the resignation of David Evans as a Non-executive Director of the Company with immediate effect and the appointment of John Dootson as Chief Financial Officer effective from 2 March 2009.

Commenting on the directorate changes, Steve Harris, Chairman of Cyprotex said: 

"David has made a significant contribution to the Company as a Non-executive Director and the Board would like to thank him for his contribution to the Company and wish him well with his future endeavours. 

The Company is very pleased to appoint John Dootson as Chief Financial Officer. John has been associated with the Company for over four years as a consultant Financial Controller and therefore has intimate knowledge of the Company's business and finances. He brings to the Company wide ranging financial expertise gained in both industry and private practice"

Notes for Editors: 

John Dootson, aged 47, has 25 years experience in both professional practice and in industry. Trained with Tenon and Ernst & Young, John has extensive managerial experience in major accounting practices and has worked on a wide range of projects including London Stock Exchange flotations and circulars, corporate governance, company acquisitions and disposals and specialist advice to growing SMEs. John has also worked in a number of roles in Industry at Financial Controller and Director level, including seven years within the senior head office finance team of BTP plc, a former FTSE250 specialty chemical manufacturer with over 50 sites worldwide prior to its sale to Clariant AG for £1.1bn.

John is a Fellow of the Institute of Chartered Accountants in England and Wales and for the last four years he has assisted Cyprotex in a management consultative role that has included all aspects of finance and reporting.

The following information relating to Mr. Dootson is provided in compliance with the provisions of Rule 17, Schedule Two, paragraph (g) of the AIM Rules for Companies

 

Full name and age: John Kevin Dootson, age 47.

Present directorships: Downham Mayer Clarke Limited

 

Directorships during the past five years:  Downham Mayer Clarke Limited

Mr. Dootson has not been a director of any company which has been wound up or placed in administration or receivership.

Mr. Dootson holds no shares in the Company. 

There are no further disclosures to be made in respect of Mr. Dootson under the provisions of Rule 17, Schedule Two, paragraph (g) of the AIM Rules for Companies.

 

Enquiries:

Cyprotex PLC

 

Tony BaxterCEO 

01625 505100

Mark WarburtonCompany Secretary

 

Noble & Company Limited

 

John Llewellyn-Lloyd 

 02077632200

Sam Reynolds

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOATIMATMMITBJL
Date   Source Headline
1st Jun 20169:35 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
27th May 20165:04 pmRNSReplacement Form 8.3 - Cyprotex PLC
27th May 20164:59 pmRNSReplacement Form 8.3 - Cyprotex PLC
27th May 20164:56 pmRNSReplacement Form 8.3 - Cyprotex Plc
27th May 20164:45 pmRNSForm 8.3 - Cyprotex Plc - Replacement
27th May 20163:28 pmRNSForm 8.3 - Cyprotex
27th May 20168:59 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
25th May 20161:49 pmRNSForm 8.3 - Cyprotex PLC
24th May 201610:56 amRNSForm 8.3 - Cyprotex PLC
24th May 20168:54 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
23rd May 20169:42 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
19th May 20162:38 pmRNSNotice of AGM
19th May 201610:59 amBUSForm 8.3 - Cyprotex Plc
17th May 20167:00 amRNSLaunch of New Enhanced Version of chemPK
16th May 201610:10 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
13th May 20169:26 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
12th May 20169:37 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
11th May 20169:17 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
10th May 20169:38 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
10th May 20167:00 amRNSTrading Update
9th May 201611:35 amRNSUpdate Re General Meeting
9th May 201610:19 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
4th May 201610:08 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
3rd May 201610:35 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
29th Apr 201612:04 pmRNSForm 8.3 - Cyprotex
29th Apr 20169:38 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
28th Apr 20169:35 amRNSForm 8.5 (EPT/RI) - Cyprotex PLC
26th Apr 201611:24 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
26th Apr 20167:00 amRNSLaunch of GLP-Compliant Genotoxicity Services
25th Apr 201610:13 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
22nd Apr 20169:26 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
21st Apr 20164:53 pmRNSForm 8.3 - Cyprotex Plc
20th Apr 20164:37 pmRNSForm 8.3 - Cyprotex PLC
20th Apr 201610:05 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
18th Apr 201611:40 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
15th Apr 201610:08 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
14th Apr 201611:09 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
14th Apr 201610:10 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
13th Apr 201612:42 pmRNSReplacement Form 8.3 - Cyprotex plc
12th Apr 20161:57 pmRNSForm 8 (OPD) (Cyprotex PLC)
12th Apr 201612:18 pmRNSForm 8.3 - Cyprotex PLC
12th Apr 201611:18 amRNSForm 8.5 (EPT/RI)
12th Apr 201610:13 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
11th Apr 20165:46 pmRNSRule 2.10 Announcement
11th Apr 20163:39 pmRNSForm 8.5 (EPT/RI) - Cyprotex Plc
11th Apr 201611:05 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
8th Apr 20164:32 pmRNSRule 2.10 Announcement
8th Apr 201612:07 pmRNSForm 8.5 (EPT/RI) - Cyprotex Plc- Amendment
8th Apr 201611:05 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
7th Apr 20164:35 pmPRNForm 8.3 - Cyprotex Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.